Palliative care for patients with pulmonary fibrosis: symptom relief is essential

Lindell, Kathleen O.; Raghu, Ganesh

doi:10.1183/13993003.02086-2018

Cited by 10 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…221,229,233,234,236 • Palliative care should be considered in parallel with other treatment interventions to optimize symptom management. 235…”

Section: Discussionmentioning

confidence: 99%

“…Palliative care aims to alleviate symptom burden, especially dyspnoea and cough, address advance care planning and optimize HRQoL throughout the disease course. 231,235 Palliative care should occur in parallel with all other treatments and not be delayed until the disease is advanced. 231,236 As discussed, supplemental oxygen and PR play an important role in selfmanagement and reducing dyspnoea.…”

Section: Symptom Management and Palliative Carementioning

confidence: 99%

“…Opioids, up to a dose of 30 mg morphine daily, might safely relieve dyspnoea 3,230,231,237,238 . Evidence for the use of benzodiazepines is limited, but may be an alternative in those with dyspnoea associated with anxiety or not controlled by opioids 231,235,238,239 . Caution is required with both opioids and low‐dose benzodiazepines associated with increased hospital admissions and mortality in patients with oxygen‐dependent ILD 240 …”

Section: Special Considerations In Ctd‐ild Managementmentioning

confidence: 99%

See 2 more Smart Citations

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

et al. 2020

View full text Add to dashboard Cite

Pulmonary complications in CTD are common and can involve the interstitium, airways, pleura and pulmonary vasculature. ILD can occur in all CTD (CTD-ILD), and may vary from limited, non-progressive lung involvement, to fulminant, life-threatening disease. Given the potential for major adverse outcomes in CTD-ILD, accurate diagnosis, assessment and careful consideration of therapeutic intervention are a priority. Limited data are available to guide management decisions in CTD-ILD. Autoimmunemediated pulmonary inflammation is considered a key pathobiological pathway in these disorders, and immunosuppressive therapy is generally regarded the cornerstone of treatment for severe and/or progressive CTD-ILD. However, the natural history of CTD-ILD in individual patients can be difficult to predict, and deciding who to treat, when and with what agent can be challenging. Establishing realistic therapeutic goals from both the patient and clinician perspective requires considerable expertise. The document aims to provide a framework for clinicians to aid in the assessment and management of ILD in the major CTD. A suggested approach to diagnosis and monitoring of CTD-ILD and, where available, evidence-based, diseasespecific approaches to treatment have been provided.

show abstract

“…221,229,233,234,236 • Palliative care should be considered in parallel with other treatment interventions to optimize symptom management. 235…”

Section: Discussionmentioning

confidence: 99%

Section: Symptom Management and Palliative Carementioning

confidence: 99%

Section: Special Considerations In Ctd‐ild Managementmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

et al. 2020

View full text Add to dashboard Cite

show abstract

“…4 If patients are referred to palliative care, it mainly happens after ICU admission (20%) and in only 4% of patients prior to ICU admission. 4,5 Early involvement of palliative care is recommended but rarely implemented which therefore results in a high symptom burden, decreased quality of life, high rates of acute care use and hospital deaths. 6,7 Recent population-based data on the use of acute care services suggest that in ILD, the estimated financial burden of hospitalization in 2010 was over $22 million per year.…”

Section: Introductionmentioning

confidence: 99%

“…3 Other reasons include false assumptions that palliative cares should be reserved for end of life care or is synonymous with hospice, or the misconception that it may be a barrier to referral for lung transplant. 5,6,11,12 In this paper we aim to highlight the palliative care needs of patients with ILD, discuss possible barriers to access to palliative care, and create a list of triggers that may increase the number of referrals to PC services. We will also address its implications for training of palliative care specialists as well as pulmonologists during their subspecialty training.…”

Section: Introductionmentioning

confidence: 99%

Palliative Care for the Interstitial Lung Disease Patient a Must and Not Just a Need

Chaaban

McCormick

Gleason

et al. 2021

Am J Hosp Palliat Care

View full text Add to dashboard Cite

Patients with interstitial lung disease (ILD) have many unmet palliative care needs. The majority of patients with chronic ILD have poor access to a specialist in palliative medicine and that is due to several barriers. The mortality for the ILD patient is high and reaches up to 80% if admitted to the ICU with respiratory failure. Palliative care addresses symptoms in diseases where cure is unlikely or impossible. Palliative care consultation also ensures communication among patients, caregivers and providers regarding treatments, prognosis, and end of life planning. Methods: We performed a literature review on palliative care and ILD, accessing articles published since 2002. We found 71 articles related to the topic. We chose 37 that were most relevant and with no redundancy of information to include in this review. Objectives: Summarize the palliative care needs of patients with ILD, discuss the barriers to receiving palliative care, and summarize clinical practice for providing palliative care to this patient population.

show abstract

Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Shlobin,

Shen,

Wort

et al. 2024

Pulm. circ.

View full text Add to dashboard Cite

Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered complication of fibrotic ILDs, is associated with significant morbidity and mortality. Until recently, the studies of pulmonary vasodilator therapy in PH‐ILD have been largely disappointing, with some even demonstrating the potential for harm. This paper is part of a series of Consensus Statements from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative for Group 3 Pulmonary Hypertension, with prior publications covering pathogenesis, prevalence, clinical features, phenotyping, clinical trials, and impact of PH‐ILD. It offers a comprehensive review of and a holistic approach to treatment of PH‐ILD, including the management of underlying interstitial lung diseases, importance of treating the comorbidities, emphasis on importance of exercise and palliation of dyspnea, and review of the most up‐to‐date guidelines for referral for potential lung transplant work up. It also summarizes the prior, ongoing, and possibly future studies in treatment of the vascular derangement of this morbid condition.

show abstract

Palliative care for patients with pulmonary fibrosis: symptom relief is essential

Cited by 10 publications

References 22 publications

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

Palliative Care for the Interstitial Lung Disease Patient a Must and Not Just a Need

Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Contact Info

Product

Resources

About